Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Regulation FD Disclosure

Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure

Story continues below

On December1, 2018, promising results were presented from a Phase 2 clinical trial of oral Rigosertib in Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at an oral presentation during the 60th American Society of Hematology(ASH) Annual Meeting and Exposition inSan Diego. On December3, 2018, Onconova Therapeutics,Inc. (“Onconova” or the “Company”) issued a press release with respect thereto. A copy of the press release is attached hereto as Exhibit99.1 and incorporated herein by reference. The presentation materials will be available on the Company’s website.

The information disclosed under this Item 7.01 (including Exhibit99.1) is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Forward Looking Statements

Some of the statements in this report are forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended, Section21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to the Company’s expectations regarding the clinical studies, therapeutic effects and other aspects of Rigosertib and the Company’s collaborations with Symbio and Pint Pharma. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “promising,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the Company’s ability to continue as a going concern, the need for additional financing and current plans and future needs to scale back operations if adequate financing is not obtained, the success and timing of the Company’s clinical trials and regulatory approval of protocols, and those discussed under the heading “Risk Factors” in the Company’s most recent Annual Report on Form10-K and quarterly reports on Form10-Q.

Any forward-looking statements contained in this report speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this report to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Item 7.01. Financial Statements and Exhibits

(d)Exhibits.

99.1 Press release issued by the Company dated December3, 2018.


Onconova Therapeutics, Inc. Exhibit
EX-99.1 2 a18-41020_1ex99d1.htm EX-99.1 Exhibit 99.1   Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting   ·                  Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylating agent (HMA) naïve patients,…
To view the full exhibit click here

About Onconova Therapeutics,Inc. (NASDAQ:ONTX)

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

An ad to help with our costs